Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs GeneDx Holdings Corp — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $15.36 (market cap $7.11B), while GeneDx Holdings Corp trades at $67.88 (market cap $2.02B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 3.5× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 68 Days and GeneDx Holdings Corp for 19 Days on average.
| NCLH | WGS | |
|---|---|---|
Market Cap | $7.11B | $2.02B |
Volume | 22,683,268 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $167.51 |
52-Week Low | $14.12 | $34.51 |
Typical Hold Time | 68 Days | 19 Days |
Enterprise Value | $21.93B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $15.495, up 2.96% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.48, exceeding expectations, and anticipates Q3 2026 results above guidance. Valuation metrics appear attractive with a P/E of 9.39 and P/S of 0.75. Analyst consensus is a Buy with a $20.86 price target, indicating 34% upside potential. Recent news highlights strategic initiatives like earlier booking resets and new senior note offerings to manage debt.
The outlook for NCLH is positive, driven by earnings momentum and favorable analyst sentiment, but risks include persistent yield pressure and high debt levels. Investment opportunity lies in the stock's discounted valuation relative to growth prospects, though investors must monitor Caribbean pricing trends and the company's ability to sustain profitability amid macroeconomic uncertainties.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
